Cross Road Biotech Inversiones Biotecnológicas (CRB Inverbío SGECR SA) is a venture capital management firm registered with number 87 in the CNMV. CRB Inverbío manages Venture Capital Firms that invest in the development of seed stage companies in life sciences that address unmet medical needs and have the potential to grow into successful businesses. To that end, the company selects innovative projects led by prestigious scientists and entrepreneurs, providing financing, management support and strategic advice.
CRB Inverbío is based upon the expertise and successful track record in continuous value creation of Cross Road Biotech, a Spanish venture capital firm that has invested and managed eleven biotech companies since 2005. CRB Inverbío has a unique competitive advantage: the expertise, analytical capabilities and commitment to succeed of the management team: a key element to build highly successful businesses and maximize the returns to the investors.
CRB Inverbío manages Funds and Venture Capital Firms specialized in life sciences. At present the company is launching CRB Bio II, a 60M€ venture capital fund to invest in emerging companies for life sciences, an attractive opportunity to participate in one of the most powerful investment sector of the new economy.
- Area of Activity
- Venture capital
- Venture capital management company
- Company type
- Investors - Venture Capital
Almagro 1 1º derecha
Madrid, Madrid 28010, ES
P: 91 4467897
Director of Business Development
Technical and Scientific Director
CRB Inverbío manages Venture Capital Firms that invest in the development of seed stage companies in life sciences that address unmet medical needs and have the potential to grow into successful businesses.
In Spain, Biotech companies specialized in life Sciences are underfinanced compared to its European or US peers. This is due to the limited private capital available for investment in the industry. There are also other reasons:
- No investment tradition in biotech or life science among private investors.
- Very few specialized VCs operating in the Spanish market
- Bank financing for biotech is practically inexistent.
- Most public funds are in the form of grants or loans providing limited opportunities for leverage.
- Though this may probably change in the next few years, so far there have been few operations by European VCs in Spain’s biotech industry.
Although as a strategy CRB Inverbío will seek to attract other investors to its participated companies, it is important to ensure that the new Fund has resources to support its investments throughout successive investment follow-on rounds if necessary.
CRB Inverbío has the experience and know how in the Spanish venture capital market specialized in life sciences of the Management Team, led by Enrique Castellón that adds value since the beginning.